BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Henagliflozin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Henagliflozin\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06448130-6921@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Henagliflozin: Phase 4 readout est. (NCT06448130)
DESCRIPTION:Henagliflozin\, phase 4\, Type 2 Diabetes.\nStudy: Henagliflozi
 n's Impact on Prediabetes Remission\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/henagliflozin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 48130
URL:https://assetmemo.bio/drug/henagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06762223-6921@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Henagliflozin: Phase 4 readout est. (NCT06762223)
DESCRIPTION:Henagliflozin\, phase 4\, Type 2 Diabetes.\nStudy: Henagliflozi
 n on Liver Fibrosis in Patients with MASLD and T2DM\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/henagliflozin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06762223
URL:https://assetmemo.bio/drug/henagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323381-6921@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Henagliflozin: Phase 4 readout est. (NCT07323381)
DESCRIPTION:Henagliflozin\, phase 4\, Type 2 Diabetes.\nStudy: Effects of H
 enagliflozin Proline and Metformin XR on Body Composition in Geriatric Pat
 ients With Newly Diagnosed T2DM\nEstimated primary completion: 30 Septembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/henagliflozin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 23381
URL:https://assetmemo.bio/drug/henagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027774-6921@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Henagliflozin: Phase 4 readout est. (NCT07027774)
DESCRIPTION:Henagliflozin\, phase 4\, Chronic Kidney Disease.\nStudy: Effec
 t of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advance
 d Chronic Kidney Disease : A Multicenter Prospective\, Randomized Controll
 ed Trial（HERO -aCKD）\nEstimated primary completion: 30 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/henagliflozin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07027774
URL:https://assetmemo.bio/drug/henagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06818851-6921@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Henagliflozin: Phase 4 readout est. (NCT06818851)
DESCRIPTION:Henagliflozin\, phase 4\, Type 2 Diabetes.\nStudy: The Effects 
 of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Dia
 betes Patients on Insulin Therapy\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/henagliflozi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 818851
URL:https://assetmemo.bio/drug/henagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948577-6921@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Henagliflozin: Phase na readout est. (NCT07948577)
DESCRIPTION:Henagliflozin\, phase na.\nStudy: Henagliflozin on Myocardial F
 ibrosis in Obese Patients\nEstimated primary completion: October 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/henagliflozin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07948577
URL:https://assetmemo.bio/drug/henagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294495-6921@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Henagliflozin: Phase na readout est. (NCT07294495)
DESCRIPTION:Henagliflozin\, phase na.\nStudy: Effect of Henagliflozin on My
 ocardial Fibrosis in Non-Obstructive HCM: A Randomized\, Double-Blind\, Pl
 acebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR\nEstimated primary comp
 letion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/henagliflozin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07294495
URL:https://assetmemo.bio/drug/henagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
